Spruce Biosciences

Where science meets compassion to deliver targeted therapies for serious neurological disorders.

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. At the heart of everything we do is our commitment to patients and their families. They inspire us to go beyond incremental progress to develop transformative therapies born from thoughtful science that leads to meani

ngful changes in their lives. Our initial focus is developing tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies.

08/31/2026

Earlier this month, members of the Spruce team attended the National MPS Society 40th Annual Family & Scientific Conference, where we had the privilege of listening, learning and connecting with families from the Sanfilippo Syndrome Type B (MPS IIIB) community.

We are deeply grateful to the families, advocates, and caregivers who shared their stories, perspectives and the day-to-day realities of caring for someone affected by MPS. These conversations deepen our understanding, strengthen our commitment to the community, and underscore the importance of continued listening, learning and engagement.

We’re grateful to the National MPS Society for bringing the community together and creating a space for connection, support, and shared understanding.
To learn more about MPS IIIB and our planned clinical research, visit www.MPS3BStudy.com

08/12/2026

We are grateful to the Cure Sanfilippo Foundation and the National MPS Society for their combined $5.5 million strategic investment in Spruce Biosciences to help expand access to tralesinidase alfa enzyme replacement therapy (TA-ERT) for children living with MPS IIIB and help partially fund the Expanded Access Program (EAP).

In light of this milestone, our CEO Javier Szwarcberg, M.D., shared a letter with the MPS IIIB community to reflect on what industry and the patient community can accomplish when we stand together. We appreciate the leadership of the Cure Sanfilippo Foundation and the National MPS Society, and to the families whose continued engagement and commitment shape this work.

Thank you for the trust you place in us.

https://investors.sprucebio.com/news-releases/news-release-details/cure-sanfilippo-foundation-and-national-mps-society-make-55

07/14/2026

We were honored to host Terri Klein, President & CEO of the National MPS Society, this week. As one of the most dedicated advocacy leaders in the Sanfilippo and broader MPS community, Terri generously shared her time and hard-won perspective, including stories of families living with MPS IIIB and the ongoing work to advance research, mobilize support and champion this community. We're deeply grateful for the opportunity to learn directly from Terri. Her insight as an advocate, and her unwavering commitment to families affected by MPS, will continue to inform and inspire the work we do on behalf of the patients and communities we serve. Thank you, Terri, for your time, your partnership and everything you do for this community.

06/08/2026

We are grateful for Dr. Nicole Maria Muschol’s presentation of long-term clinical data on Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in patients with in patients with Sanfilippo Syndrome Type B (MPS IIIB) over the weekend at the 18th International MPS Symposium.

Sustained normalization of CSF HS-NRE, the anticipated surrogate marker for accelerated approval, alongside long-term stabilization of cognitive function, communication, and motor skills strengthens our confidence in the potential of TA-ERT and reinforces our dedication to working closely with the Sanfilippo community to responsibly advance this program through a biologics license application submission and potential U.S. FDA approval.

We are also incredibly grateful to the children, families, caregivers, and study investigators who participated in the TA-ERT clinical development program.

https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-announces-long-term-tralesinidase-alfa-enzyme

05/15/2026

May 15th is International MPS Awareness Day.

At Spruce Biosciences, our commitment to patients and their families are at the heart of everything we do. We hope to deliver medicines that make meaningful impacts
for families affected by Sanfilippo Syndrome Type B (MPS IIIB), a devastating pediatric neurodegenerative disorder that currently has no FDA‑approved therapies.

This year, we joined National MPS Society and put on our dancing shoes to help spread awareness. On this day and every day, we stand with the MPS community, listen to families and caregivers, and work tirelessly to bring hope where it’s needed most.

05/13/2026

Today, our CEO Javier Szwarcberg shared a letter with the Sanfilippo Syndrome Type B community about recent progress of our TA-ERT program.

He highlighted our ongoing regulatory progress, the latest encouraging clinical data from our clinical program and outlined our plans for both a U.S. expanded access program and global confirmatory study.

We’re grateful for the generous support of the patients, families and community, as well as ongoing partnership with Cure Sanfilippo Foundation and National MPS Society.

05/12/2026

Our CEO Javier Szwarcberg recently joined Karen Jagoda on the Empowered Patient Podcast to discuss Sanfilippo Syndrome Type B (also known as MPS IIIB), the challenges of delayed diagnosis and the urgent unmet need for an effective treatment.

Javier speaks to his own personal commitment to rare disease and the company’s driving mission to develop transformative therapies that lead to meaningful changes in patient lives.

Listen to the full episode here: http://empoweredpatientradio.com/enzyme-replacement-therapy-for-sanfilippo-syndrome-type-b-with-dr-javier-szwarcberg-spruce-biosciences

Address

611 Gateway Boulevard
South San Francisco, CA
94080

Website

https://www.sprucebiosciences.com/

Alerts

Be the first to know and let us send you an email when Spruce Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Spruce Biosciences:

Want your business to be the top-listed Business in South San Francisco?